TREM2 agonist VG-3927 for Alzheimer's: promising or too early to say?

Preclinical data and phase 1 results have been published for VG-3927, a small molecule that activates the TREM2 receptor on microglia. According to the authors, the drug penetrates the CNS, engages its target, and is well tolerated. This is an early stage of development: efficacy in patients with Alzheimer's disease has not been shown yet, and larger studies are needed. What we'll discuss: — How convincing is targeting microglia via TREM2, either as an alternative or an addition to anti-amyloid therapy? What risks do you see, for example excessive inflammatory activation? — Which endpoints would you consider sufficient to judge the benefit of such a drug: biomarkers (CSF, PET) or clinical scales? — How do you explain to students the role of TREM2 in Alzheimer's pathogenesis, and why are variants of this gene considered a risk factor? For USMLE preparation, this topic helps connect microglia, TREM2 as a risk gene, and the search for targets beyond amyloid. Full article: drasiiavinograd.com/blog/trem2-agonist-vg-3927-in-alzheimer-s-usmle-re Source: Nature Medicine nature.com/articles/d41591-026-00055-x